StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for HRMY yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $30.96 | $30.76 | -0.65% | 0.5M |
| 05-15 | $30.90 | $30.09 | -2.62% | 0.5M |
| 05-18 | $30.13 | $29.83 | -1.00% | 0.7M |
| 05-19 | $29.93 | $30.44 | +1.70% | 0.7M |
| 05-20 | $30.49 | $31.38 | +2.92% | 0.7M |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $215.39M | $868.45M | $624.68M | $385.22M |
Operating Income | $37.29M | $208.47M | $169.91M | $104.42M |
Net Income | $32.49M | $158.69M | $136.20M | $85.34M |
EPS (Diluted) | $0.55 | $2.71 | $2.32 | $1.46 |
Total Assets | $1.27B | $1.27B | $1.21B | $1.11B |
Total Liabilities | $361.48M | $401.41M | $373.10M | $334.93M |
Cash & Equivalents | $589.40M | $752.50M | $647.00M | $546.05M |
Free Cash Flow OCF − CapEx | Not available | $347.89M | $221.84M | $113.18M |
Shares Outstanding | 57.87M | 57.73M | 57.60M | 57.54M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.